Researchers assessed whether febuxostat increased the risk of developing cardiovascular events, death from cardiac-cause, and all-cause mortalities.
Researchers investigated the association between gout, urate-lowering therapy use, and the risk of developing type 2 diabetes.
Researchers evaluated the adrenocorticotropic hormone as an alternative therapeutic option for acute gout, and its potential mechanisms of action.
Patients with gout receiving urate lowering therapy by a treat-to-target approach demonstrate a reduced burden of monosodium urate crystals detected on ultrasound.
From 1990 to 2017, the burden of gout increased across the world.
Researchers determined the association between gout and epilepsy and the risk for epilepsy in patients with gout.
Researchers assessed whether initiating guideline-concordant gout therapy improved arterial function and reduced inflammation.
Researchers investigated the association between gout and the risk for erectile dysfunction.
In separate randomized controlled trials, allopurinol had no significant effect on kidney function decline.
The open-label, prospective study (GRECCO-19) assessed the effect of treatment with low-dose colchicine on cardiac and inflammatory biomarkers as well as clinical outcomes.